Xuantai Pharmaceutical: Sales in the US market have not been significantly affected, actively expanding international markets.

Xuantai Pharmaceuticals stated on May 12th on the interactive platform that since the beginning of this year, the U.S. market has been facing uncertainties due to bilateral tariff adjustments, which may have a negative impact on the company's product sales in the U.S. market. However, as of the first quarter of 2025, the company has not made significant adjustments to its sales in the U.S. market; at the same time, the company has actively explored other international markets in recent years and has already reached product cooperation agreements with relevant distributors in countries or regions such as Canada, Australia, Israel, Southeast Asia, Gulf countries, and Central and South America. Some products have been approved and launched in their respective markets, which will have a positive impact on the company's performance.